Sunitinib (Sutent): targets multiple receptor tyrosine kinases, including VEGFR, and has shown potential in reducing tumor growth and metastasis in pancreatic cancer (Doi et al., 2012). The gene discussed is KDR; the disease is familial pancreatic carcinoma.